Mevidalen

DB19034InvestigationalSmall molecule

Mevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia...

Mechanism: Pharmacologically active on Dopamine receptor D1
Curator reviewed
Formula / weight: C₂₄H₂₉Cl₂NO₃ · 450.4 g/mol (avg)
Also known as: 2-(2,6-dichlorophenyl)-1-((1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl)ethanone · Ethanone, 2-(2,6-dichlorophenyl)-1-((1s,3r)-3,4-dihydro-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-2(1h)-isoquinolinyl)-
Code names: LY-3154207

Resolves to

Compound

UNII4A3702A96FCAS1638667-79-4ChEMBLCHEMBL3421729

Structure

InChIKeyXHCSBQBBGNQINS-DOTOQJQBSA-NSMILESC[C@@H]1N([C@@H](CO)CC2=C(CCC(C)(C)O)C=CC=C12)C(=O)CC1=C(Cl)C=CC=C1Cl

Targets

P21728DRD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mevidalen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account